TY - JOUR
T1 - The management of mucous membrane pemphigoid and pemphigus
AU - Knudson, Richelle M.
AU - Kalaaji, Amer N.
AU - Bruce, Alison J.
PY - 2010
Y1 - 2010
N2 - Mucous membrane pemphigoid and pemphigus vulgaris are autoimmune blistering disorders in which many similar drugs and therapeutic strategies are utilized. In general, localized disease can be treated with topical agents. In contrast, patients with more severe and progressive disease usually require a combination of systemic corticosteroids and immunosuppressive medications. Oral corticosteroids, adjuvant immunosuppressive agents, antibiotics such as dapsone and immunomodulatory procedures like intravenous immunoglobulin are the main therapeutic agents used in treating these two disorders. Much of the morbidity and mortality associated with these disorders are related to the sites involved and to the drugs used for therapy. Treatment should be individualized based on severity, extent, and rate of progression of disease, comorbidities, and age of the patient. Serum levels of specific autoantibodies and indirect immunofluorescence titers, in certain cases, can be used to monitor response to therapy.
AB - Mucous membrane pemphigoid and pemphigus vulgaris are autoimmune blistering disorders in which many similar drugs and therapeutic strategies are utilized. In general, localized disease can be treated with topical agents. In contrast, patients with more severe and progressive disease usually require a combination of systemic corticosteroids and immunosuppressive medications. Oral corticosteroids, adjuvant immunosuppressive agents, antibiotics such as dapsone and immunomodulatory procedures like intravenous immunoglobulin are the main therapeutic agents used in treating these two disorders. Much of the morbidity and mortality associated with these disorders are related to the sites involved and to the drugs used for therapy. Treatment should be individualized based on severity, extent, and rate of progression of disease, comorbidities, and age of the patient. Serum levels of specific autoantibodies and indirect immunofluorescence titers, in certain cases, can be used to monitor response to therapy.
KW - Cicatricial pemphigoid
KW - Mucous membrane pemphigoid
KW - Pemphigus vulgaris
KW - Therapy
UR - http://www.scopus.com/inward/record.url?scp=77952683428&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=77952683428&partnerID=8YFLogxK
U2 - 10.1111/j.1529-8019.2010.01323.x
DO - 10.1111/j.1529-8019.2010.01323.x
M3 - Review article
C2 - 20597945
AN - SCOPUS:77952683428
SN - 1396-0296
VL - 23
SP - 268
EP - 280
JO - Dermatologic Therapy
JF - Dermatologic Therapy
IS - 3
ER -